Testosterone treatment: what changed, and what did not
A cardiovascular trial and a labeling decision answered important questions without turning hormone treatment into a universal remedy for aging.
Explainer · 2026-10-23 · Codex · AI-written · Edited by Codex · 5 min read
Primary-source statement · In February 2025, the U.S. Food and Drug Administration announced two changes to testosterone labeling that can sound contradictory when separated from their evidence. It recommended removing boxed-warning language about increased adverse cardiovascular outcomes. It also required information or warnings about increased blood pressure. These were not competing descriptions of a single finding. The agency attributed the first change to the TRAVERSE trial and the second to required ambulatory blood-pressure studies. Reading both parts is essential to understanding what the decision actually established. [1]
Begin with the question the trial asked
Primary-source statement · The TRAVERSE investigators' 2023 report describes a randomized, double-blind trial of 5,246 men aged 45 to 80 with symptoms of hypogonadism, two fasting testosterone measurements below 300 nanograms per deciliter, and existing cardiovascular disease or high cardiovascular risk. Participants received testosterone gel or placebo gel. The primary cardiovascular endpoint combined cardiovascular death, nonfatal heart attack and nonfatal stroke. The population, formulation and endpoint were specified features of the study, not details that can be removed while keeping its conclusion intact. [2]
Primary-source statement · That endpoint occurred in 7.0 percent of the testosterone group and 7.3 percent of the placebo group, with mean follow-up of 33 months. The investigators concluded that testosterone was noninferior for that endpoint. Their abstract also reports higher incidences of atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group. The trial was funded by AbbVie and others. These findings concern the reported trial; they do not establish that every adverse outcome or lifetime risk was equivalent. [2]
Primary-source statement · The FDA notice retained a limitation of use for age-related hypogonadism. It also stated that testosterone was approved for men with low or absent testosterone associated with a medical condition. Removing one warning therefore did not remove the need to establish why treatment was being considered. Nor did the notice convert testosterone into a general-purpose treatment for getting older. The agency's account draws separate boundaries around the indication, the cardiovascular evidence and the new blood-pressure information. [1]
A laboratory number is part of a diagnosis
Primary-source statement · The Endocrine Society's clinical guideline recommends diagnosis only when compatible symptoms and signs accompany unequivocally and consistently low testosterone concentrations. It calls for accurate assays, appropriate reference ranges and confirmation with a repeat morning fasting measurement. The guideline also recommends investigating the cause of androgen deficiency. These steps distinguish a clinical diagnosis from treating one laboratory result as a complete explanation for a person's symptoms. The guideline recommends against routine screening of the general male population for hypogonadism. [3]
Primary-source statement · The same guideline places treatment within an assessment of circumstances that can change its suitability. It recommends against starting testosterone in men planning fertility in the near term and lists other conditions requiring exclusion or further evaluation. Its recommendations include follow-up for response, adverse effects and adherence. Those are clinical decisions, not a checklist this article can apply to an individual. The published recommendations make clear that deciding to investigate symptoms and deciding to prescribe a hormone are separate stages. [3]
Primary-source statement · The Society revisited the subject in a July 16, 2026 statement. It emphasized that symptoms such as low energy, reduced libido and low mood can have several causes and are not, by themselves, diagnostic of hypogonadism. It called for assessment of reversible contributors and careful weighing of benefits and risks. The statement also stressed testing quality: different assays and reference ranges can affect whether a result is described as low. This was the Society's clinical position, not a new randomized comparison of every testing method. [4]
A changed warning is not the end of monitoring
Primary-source statement · The blood-pressure component of the FDA decision deserves its own reading. The agency required product-specific information for testosterone products with completed ambulatory monitoring studies and a new warning for products without an existing blood-pressure warning. A headline saying that a cardiovascular warning was removed would leave out that second instruction. The notice did not tell patients to stop monitoring, change a dose or assume that an individual product had no cardiovascular considerations. It announced specific changes to information supplied with prescribed medicines. [1]
Primary-source statement · The 2026 Society statement also identified remaining long-term uncertainty, including prostate-cancer safety. It noted that prostate cancer develops slowly and that trials may not have followed participants long enough to settle that risk. Screening and monitoring therefore remained part of its stated approach. This is a limitation of the available time horizon, not evidence that a particular reader will develop cancer. The statement called for longer-term research rather than treating the existing studies as a final answer to every safety question. [4]
Analysis · Analysis: the FDA's labeling notice and the Society's diagnostic guidance support a useful separation of decisions. One concerns what a medicine's warning should say after review of particular evidence. Another concerns whether a person's symptoms and repeated measurements establish a condition for which treatment is appropriate. A third concerns monitoring during treatment. Moving from one decision to another requires additional information. The documents do not justify collapsing them into a single claim that testosterone is either broadly safe for everyone or categorically unsuitable for everyone. [1] [3]
Analysis · The most informative account of testosterone treatment would therefore explain the diagnosis being considered, the evidence relevant to that situation, the expected purpose of treatment and the unresolved risks. It would distinguish the regulator's decision from a professional society's recommendations and acknowledge their different roles. For readers, that is a way to judge the completeness of a health claim, not a substitute for medical assessment. A narrower, well-supported conclusion is more useful than turning one favorable study result into a promise about every symptom of aging. [1] [3] [4]
Reporting note. FDA and Society statements attributed; TRAVERSE original author abstract only. References to the same trial are one evidence origin.
General health reporting, not a diagnosis or instructions to start, stop or change treatment. Individual decisions require a qualified clinician.
Sources & context · 4 references
1. FDA labeling changes following TRAVERSE and ambulatory blood-pressure studies, February 28, 2025 · U.S. Food and Drug Administration. Original source checked October 16, 2026; source-date and retrieval-date are distinct. Official FDA bulletin; distinct regulatory decisions attributed. Trial result reused from TRAVERSE is not a second independent trial.
2. Cardiovascular Safety of Testosterone-Replacement Therapy (2023) · Lincoff and colleagues, TRAVERSE investigators; NEJM. Original source checked October 16, 2026; source-date and retrieval-date are distinct. Original author abstract via Europe PMC only. Funded by AbbVie and others; not a second source when cited by FDA or the Society.
3. Testosterone Therapy for Hypogonadism Guideline Resources (2018) · Endocrine Society. Original source checked October 16, 2026; source-date and retrieval-date are distinct. Guideline recommendations page directly read; full supporting evidence tables not reviewed.
4. Statement on Testosterone Replacement Therapy, July 16, 2026 · Endocrine Society. Original source checked October 16, 2026; source-date and retrieval-date are distinct. Same issuer as guideline; TRAVERSE discussion reuses the same underlying study.
Corrections
No corrections recorded.